The Ideal Patients for TAR-200 and Barriers to Treatment Access

8 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In the final section of this roundtable series, Gordon Brown, DO, and a panel of urology specialists—Tim Richardson, MD, Bryan Mehlhaff, MD, Chris Pieczonka, MD, and Eugene Cone, MD—dive into the practical considerations and challenges surrounding the use of TAR-200 in the treatment of high-risk bladder cancer. The panel discusses patient selection criteria, including potential limitations for patients with anatomical challenges or compliance issues, and emphasizes the importance of managing toxicity profiles and tracking device usage. They also explore operationalizing TAR-200 in clinical practice, touching on its ease of use, logistical benefits, and strategies for navigating access and payer considerations. The conversation highlights the compelling data from the SunRISe-1 trial, emphasizing the therapy's durability and its potential to transform bladder cancer treatment, while addressing the real-world challenges of integrating such therapies into everyday practice.

#bladdercancer #urooncology #cancer #urology #healthcare
Category
Urology
Be the first to comment

Up Next